Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Eyenovia, Inc. EYEN NASDAQ

NASDAQ Capital Marke • Healthcare • Biotechnology • US • USD

SharesGrow Score
36/100
0/6 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow

Eyenovia, Inc. (EYEN) — Analyst outlook / Analyst consensus target is. Based on 7 analyst ratings, the consensus is bullish — 2 Buy, 5 Hold.

EYEN Analyst Ratings

Hold
7
Ratings
2 Buy
5 Hold
Based on 7 analysts giving stock ratings to Eyenovia, Inc. in the past 3 months
Rating breakdown
Buy
2 29%
Hold
5 71%
29%
Buy
2 analysts
71%
Hold
5 analysts
0%
Sell
0 analysts

People Also View

IBRX
IBRX
ImmunityBio, Inc.
$7.60
+4.11%
 CDTX
CDTX
Cidara Therapeutics, Inc.
$221.38
+0.00%
 KOD
KOD
Kodiak Sciences Inc.
$45.07
+7.44%
 OCUL
OCUL
Ocular Therapeutix, Inc.
$8.76
-1.13%
 ARDX
ARDX
Ardelyx, Inc.
$6.33
+0.16%
 LXRX
LXRX
Lexicon Pharmaceuticals, Inc.
$1.75
+2.34%
 DRTS
DRTS
Alpha Tau Medical Ltd.
$7.83
+2.49%
 GLSI
GLSI
Greenwich LifeSciences, Inc.
$26.02
-5.35%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message